Lumasiran

OXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLE

100 mg solución inyectableSpainMarketedAuthorised 30 Dec 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

OxlumoEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lumasiran

OXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLE

100 mg solución inyectableSpainMarketedAuthorised 30 Dec 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

OxlumoEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

OxlumoUnited States · 94.5MG BASE/0.5ML · solution · Alnylam Pharms INC

Packs

Pack	Code	Status
OXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLE, 1 vial de 0,5 ml	729970

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lumasiran
Strength: 100 mg
Dosage form: solución inyectable
Route: vía subcutánea
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 30 Dec 2020
Registration: 1201496001
Marketing authorisation holder: Alnylam Netherlands B.V.
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/20/1496